Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st

DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharma (Flamel Technologies S.A. Acquired Avadel)  (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at Stifel's Third Annual CNS Day, which is being held on March 31^st.

Avadel’s fireside chat is scheduled for 3 p.m. ET on Wednesday, March 31^st. A live webcast of this event, as well as an archived recording, will be available at (click here), as well as on Avadel’s website, www.avadel.com, for 90 days from being made available.

Contacts:

        Tom McHugh
        Chief Financial Officer
        Phone: (636) 449-1843
        Email: tmchugh@avadel.com
        
        Tim McCarthy
        LifeSci Advisors, LLC
        Phone: (212) 915-2564
        Email: tim@lifesciadvisors.com